NCI declares state of crisis in trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

An NCI report concluded that our clinical trial system is nearing a “state of crisis.” This seems like a case of new report, same conclusion.

An NCI report concluded that our clinical trial system is nearing a "state of crisis." This seems like a case of new report, same conclusion. "A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program," identified reasons for our system's lack of production including the time it takes to organize and launch a trial: More than two years of slugging through a Kafkaesque maze of bureaucracy and, if the trial finishes at all, the compound or therapy has a good chance of being out of date. Randomized controlled trials are still the gold standard for cancer agents to move from bench to bedside. We need to make it a national priority to streamline this overwrought process.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.